BRAF mutation

Understanding its histological features and immunohistochemical profile facilitates its diagnosis and differential diagnosis, including CK20 positivity and Ki-67 negativity in the superficial layer, and high Ki-67 expression with negative CK20 staining in the deep layer. KRAS gene mutation is also an important diagnostic feature.

However, in patients with BRAF-mutated melanomas, those who received BRAF inhibitors exhibited improved survival outcomes in advanced disease stages (p = 0.0025). Our study indicates that BRAF-mutated melanoma patients with distant metastases receiving BRAF inhibitors have significantly improved survival compared to those not receiving targeted therapy, supporting the clinical benefit of BRAF inhibitor use in appropriately selected patients.

P1/2, N=77, Suspended, University of California, Davis | Trial completion date: Jan 2030 --> Jan 2034 | Recruiting --> Suspended | Trial primary completion date: Jan 2026 --> Dec 2030

Melanoma arising in a blue nevus represents an aggressive neoplasm, highlighting the importance of early biopsy and multidisciplinary evaluation. The application of immunohistochemistry and molecular profiling in atypical presentations that mimic other neoplasms represents a valuable tool for diagnosis, prognosis, and treatment planning in rare melanoma subtypes.

This study establishes a high-performance inflammatory pathway-based prognostic model for melanoma and demonstrates that driver mutation subtypes differentially shape the immune microenvironment landscape. CCNE1 functions as a key oncogenic immune regulator whose modulation of antigen presentation and immune checkpoint expression is contingent on mutational context, most prominently in NF1-mutant tumors, underscoring the value of mutation-informed personalized immunotherapy strategies in melanoma.

Prognostic accuracy improved when tumor genotype was combined with the expression of activator of HSP90 ATPase activity 1 (AHSA1) and thioredoxin domain-containing 5 (TXNDC5), involved in ER-associated protein folding. These findings define a distinctive proteomic signature in BRAF-mutated CRC, characterized by dysregulated protein folding associated with ER stress and supporting the development of targeted therapies and more precise prognostic models.

Consequently, the management of elderly patients with colorectal SSLs requires individualized decision-making integrating lesion-related risk, procedural burden, frailty, life expectancy, and the quality of prior colonoscopic examinations. This review summarizes current evidence regarding colorectal SSLs and discusses practical considerations for individualized management in elderly patients, with particular emphasis on balancing oncologic benefit against procedural risk and long-term surveillance burden in an aging society.

Molecular-risk stratification and integrated modeling identify clinically meaningful prognostic groups in CRLM. These findings support incorporation of genomic profiling into precision surgical and transplant evaluation, while emphasizing the need for prospective validation.

P2, N=35, Completed, Melanoma Institute Australia | Active, not recruiting --> Completed

P1, N=31, Recruiting, M.D. Anderson Cancer Center | Not yet recruiting --> Recruiting

This study validated the hypothesis that Trp53 deletion and Braf mutation promote the progression of PTC to ATC through ultrasound monitoring and computer modeling. Certain PTCs with the potential for dedifferentiation exhibit a specific molecular expression profile, which may represent potential therapeutic targets.

The patient received various treatment regimens, including toripalimab monotherapy, combination therapy with anlotinib, and combination therapy with temozolomide. Ultimately, surgical resection of the pancreatic and spleen metastases revealed a BRAF V600 mutation, permitting successful transition to targeted therapy with dabrafenib plus trametinib...This case report, along with the subsequent literature review, emphasizes the need for continued treatment and vigilance of molecular monitoring in patients with advanced melanoma, as well as the critical role of multidisciplinary team collaboration in managing complex metastases. Surgical resection and targeted therapy might yield favorable outcomes for select patients with melanoma and pancreatic and splenic metastases.